From MarketBeat:

The CEO of Alpine Immune Sciences, Inc., Mitchell Gold, sold 29,573 shares of ALPN stock for an average price of $20.04. The total value sold was almost $600,000. This transaction was disclosed in a filing with the Securities & Exchange Commission. Gold has also sold significant shares of this stock in the previous month.

Shares of ALPN traded down $0.30 during trading on Wednesday, to $19.92. The company has a 52-week low of $5.81 and a high of $20.94. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -16.60, and a beta of 1.37. The company recently reported quarterly earnings results, with an analyst consensus estimate of ($0.35) per share.

A number of large investors have recently made changes to their positions in Alpine Immune Sciences. These institutions include Bank of New York Mellon Corp, Royal Bank of Canada, American International Group Inc, JPMorgan Chase & Co, and California State Teachers Retirement System. In total, the institutions own 75.17% of the company’s stock.

Several brokerages have commented on ALPN, with Wedbush, Morgan Stanley, Oppenheimer, Berenberg Bank, and HC Wainwright providing ratings. Six research analysts have rated the stock with a buy rating, and the company has a consensus rating of “Buy” and a consensus price target of $25.00.

Alpine Immune Sciences, Inc. operates as a clinical-stage immunotherapy company, with a focus on creating immunotherapies for autoimmune and inflammatory diseases through protein engineering technologies. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.



Read more: Insider Selling: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) CEO Sells 29,573 Shares of Stock